ImmunGene gets grant for anti-cancer technology development
ImmunGene’s technology empowers monoclonal antibodies targeted to tumor cells by fusing them to immune effector molecules; that is, cytokine, chemokine and co-stimulatory molecules, thereby combining the specificity of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.